ASH 2024: Top abstracts in ALL

307

Efficacy and Toxicity of Fixed Dose Versus Reduced/PK-Adjusted Dose Pegaspargase in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001

Melissa A. Burns

16:30

308

Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial

Daniel J. DeAngelo

16:45

309

A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009

Martin Schrappe

16:30

310

Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes

Erica Brivio

16:45

311

Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001

Lynda M. Vrooman

17:00

312

Efficacy and Safety of Adding Blinatumomab to First-Line Treatment for Chinese Children with B-Cell Acute Lymphoblastic Leukemia

Peijing Qi

17:15

313

Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma

Haley Newman

16:00

1434

Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the GRAALL-2014 Trial

Marie Balsat

17:30 (poster session)

1

Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731

Rachel E. Rau

14:00

634

TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL

Andrew Hughes

17:15

636

CD127-Directed Immunotherapy with Lusvertikimab Outperforms Imatinib in Preclinical ABL-Class-Fusion-Positive BCP-ALL

Anna Dietterle

17:45

1420

Liver Steatosis and Metabolic Toxicities in Acute Lymphoblastic Leukemia Adults Undergoing Asparaginase-Based Therapy: Findings from a Non-Invasive Assessment Study

Fausto A Rios-Olais

17:30 (poster session)

1421

Meta-Analysis of Complete Remission Rates Following First-Line Salvage Treatment after Anti-CD19 CAR-T Failure in Adult Patients with Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia

Jaromir Tomasik

17:30 (poster session)

1422

Safety and Efficacy Results of Dose-Adjusted Inotuzumab Ozogamicin in Adults with B Cell Acute Lymphoblastic Leukemia: A Retrospective Single-Center Experience

Erlie Jiang

17:30 (poster session)

727

Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular Features

Walid Macaron

10:30

728

Older Age and TP53 Mutations Are Predictors for the Development of Therapy-Related Myeloid Neoplasms in Adults Undergoing Frontline Therapy for Acute Lymphoblastic Leukemia

Roberta Santos Azevedo

10:45

729

TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Ibrahim Aldoss

11:00

730

Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

Gunnar Cario

11:15

732

Dose Optimization of Inotuzumab Ozogamicin in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Daniel J. DeAngelo

11:45

835

Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820

Sabina Chiaretti

14:45

836

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial

Shanshan Suo

15:00

837

Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse

Nicholas J. Short

15:15

838

Immunomodulatory Effect of Dasatinib Plus Blinatumomab Versus Ponatinib Plus Blinatumomab in Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia Patients

Michela Ansuinelli

15:30

839

Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

Jieping Lin

15:45

840

Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation

Heike Pfeifer

16:00

961

Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013

Nicola Goekbuget

16:30

962

Prognostic Impact of the Genetic Risk at Baseline Associated to the MRD Clearance in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Preliminary Results of Pethema LAL19 Trial

Anna Torrent

16:45

963

Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes

Elias Jabbour

17:00

965

Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

Susana Rives

17:30

966

CD19-CAR T Cells as Definitive Consolidation for Older Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study

Ibrahim Aldoss

17:45